Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
An epigenetic bifunctional that toggles between transactivation and repression.
Journal: bioRxiv : the preprint server for biology
Published: March 27, 2026
BCL-XL Dependence is a Subtype Agnostic Actionable Feature of Difficult-to-Treat Kidney Cancers.
Journal: bioRxiv : the preprint server for biology
Published: December 19, 2025
Detection and monitoring of translocation renal cell carcinoma via plasma cell-free epigenomic profiling.
Journal: bioRxiv : the preprint server for biology
Published: September 15, 2025
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: September 15, 2025
LASER: A Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for RCC.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 13, 2025
Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: September 05, 2025
Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: August 01, 2025
Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma.
Journal: The Journal of clinical investigation
Published: May 19, 2025
CDK4/6 Inhibition With Abemaciclib in Patients With Previously Treated Advanced Renal Cell Carcinoma.
Journal: Clinical genitourinary cancer
Published: January 13, 2025
A framework for target discovery in rare cancers.
Journal: bioRxiv : the preprint server for biology
Published: November 01, 2024
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer.
Journal: European urology oncology
Published: August 19, 2024
TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: August 16, 2024
Last Updated: 09/26/2026